{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:21:56Z","timestamp":1792110116871,"version":"4.4.0"},"reference-count":6,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2018,8,1]]},"DOI":"10.1001\/jamaoncol.2017.3993","type":"journal-article","created":{"date-parts":[[2018,1,11]],"date-time":"2018-01-11T16:56:35Z","timestamp":1515689795000},"page":"1123","source":"Crossref","is-referenced-by-count":283,"title":["Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic Radiation"],"prefix":"10.1001","volume":"4","author":[{"given":"Allison M.","family":"Martin","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Dana-Farber\/Brigham and Women\u2019s Cancer Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel N.","family":"Cagney","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana-Farber\/Brigham and Women\u2019s Cancer Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Catalano","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts"},{"name":"Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Alexander","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana-Farber\/Brigham and Women\u2019s Cancer Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda J.","family":"Redig","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon D.","family":"Schoenfeld","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana-Farber\/Brigham and Women\u2019s Cancer Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayal A.","family":"Aizer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana-Farber\/Brigham and Women\u2019s Cancer Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"cld170018r1","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/01.nrl.0000080951.78533.c4","article-title":"Cerebral radiation necrosis.","volume":"9","author":"Giglio","year":"2003","journal-title":"Neurologist"},{"issue":"1","key":"cld170018r2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1684\/ejd.2014.2471","article-title":"Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroids.","volume":"25","author":"Chasset","year":"2015","journal-title":"Eur J Dermatol"},{"issue":"7","key":"cld170018r3","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"cld170018r4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"cld170018r5","doi-asserted-by":"crossref","first-page":"9507","DOI":"10.1200\/JCO.2017.35.15_suppl.9507","article-title":"Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: results of the phase II study CheckMate 204.","volume":"35","author":"Tawbi","year":"2017","journal-title":"J Clin Oncol"},{"key":"cld170018r6","doi-asserted-by":"crossref","first-page":"9508","DOI":"10.1200\/JCO.2017.35.15_suppl.9508","article-title":"A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC).","volume":"35","author":"Long","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2668527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T10:20:54Z","timestamp":1603621254000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2017.3993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,1]]},"references-count":6,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2017.3993","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8,1]]}}}